RecruitingNot ApplicableNCT07317830

Effects of Different Vitamin D3 Formulations in Vitamin D-Deficient Adults

The Effects of Eight Weeks of Supplementation With Two Vitamin D₃ Formulations in Adults With Subclinical and Clinical Vitamin D Deficiency: A Randomized Controlled Superiority Pilot Trial


Sponsor

Center for Health Sciences, Serbia

Enrollment

20 participants

Start Date

Dec 15, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This randomized controlled superiority pilot trial will evaluate the efficacy of two vitamin D3 formulations administered over eight weeks in adults with subclinical or clinical vitamin D deficiency. The study will compare changes in serum 25-hydroxyvitamin D concentrations between formulations, as well as the proportion of participants who will achieve vitamin D sufficiency. Both formulations are expected to improve vitamin D status, with the hypothesis that one formulation will demonstrate superior bioavailability, resulting in greater and faster increases in circulating 25-hydroxyvitamin D. The findings will provide preliminary evidence to inform formulation selection and dosing strategies for correcting vitamin D deficiency and will support the design of larger, confirmatory trials.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria8

  • Adults aged 18 years and over
  • Serum 25(OH)D \< 75 nmol/L
  • BMI 18.5 - 29.9 kg/m2
  • Free of clinically significant acute disorders and severe chronic diseases
  • No planned travel to high-UV destinations or tanning bed use during the trial
  • Willing to avoid non-study vitamin D supplements
  • Able to give written informed consent and comply with study visits
  • Submitted informed consent

Exclusion Criteria8

  • Pregnancy of breast feeding
  • Underweight or obesity
  • History of any dietary supplement use within 8 weeks before screening
  • Medications that materially alter vitamin D metabolism or calcium balance
  • Subjects with a history of medicine or alcohol abuse
  • Abnormal values for lab clinical chemistry (\> 2 SD)
  • Unwillingness to return for follow-up analysis
  • Participation in other clinical trials within 60 days prior to screening

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTExperimental 1 (powdered supplement)

Active powdered ingredient (2,000 IU/d)

DIETARY_SUPPLEMENTExperimental 2 (oily supplement)

Active oily ingredient (2,000 IU/d)


Locations(1)

Center for Health Sciences

Belgrade, Serbia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07317830


Related Trials